Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of CBP-174 After Oral Administration

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of CBP-174 After Oral Administration

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CBP-174 (Primary)
  • Indications Pruritus
  • Focus Adverse reactions; First in man
  • Sponsors Connect Biopharma Australia

    • Most Recent Events

    • 30 Aug 2022 According to a Connect Biopharma Holdings Limited media release, a total of 72 subjects were dosed with 8 subjects included in each cohort, whereby 54 and 18 subjects received CBP-174 and placebo, respectively.
    • 30 Aug 2022 Results presented in a Connect Biopharma Holdings Limited Media Release.
    • 14 Jun 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top